HER2-positive Breast Cancer Clinical Trials in Beijing, Beijing Municipality
12 recruitingBeijing, Beijing Municipality, China
Showing 1–12 of 12 trials
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled78 locationsNCT07043725
Recruiting
Phase 3
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.540 enrolled1 locationNCT07377643
Recruiting
Phase 2Phase 3
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
HER2-positive Breast CancerPyrotinib Treatment
Cancer Institute and Hospital, Chinese Academy of Medical Sciences964 enrolled1 locationNCT06958627
Recruiting
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
HER2-positive Breast Cancer
Shu Wang171 enrolled1 locationNCT06722599
Recruiting
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
HER2-positive Breast Cancer
Shu Wang2,916 enrolled1 locationNCT06722612
Recruiting
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
HER2-positive Breast Cancer
Shu Wang8,077 enrolled1 locationNCT06711068
Recruiting
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
HER2-positive Breast Cancer
Shu Wang285 enrolled1 locationNCT06711055
Recruiting
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
HER2-positive Breast Cancer
Shu Wang519 enrolled1 locationNCT06700369
Recruiting
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
HER2-positive Breast Cancer
Shu Wang2,806 enrolled1 locationNCT06693024
Recruiting
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
HER2-positive Breast Cancer
Shu Wang2,092 enrolled1 locationNCT06693037
Recruiting
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
HER2-positive Breast CancerEarly Stage Breast Cancer
Peking Union Medical College Hospital300 enrolled1 locationNCT06035016
Recruiting
Phase 2
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
HER2-positive Breast Cancer
Peking University104 enrolled1 locationNCT04481932